Singular Genomics Systems(US:OMIC) Globenewswire·2025-02-24 13:00Core Insights - Singular Genomics Systems, Inc. announced key development milestones for its G4X™ Spatial Sequencer at the AGBT conference, emphasizing its role in advancing precision medicine [1] Group 1: G4X Early Access Program - The G4X Early Access Program is currently active at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback on the platform's real-world potential [2] - Early access sites have reported high throughput and quality data generation across multiple sample types, aligning with the needs of the spatial biology field [3] - Singular plans to expand the early access program to additional sites in Q2, with pre-orders for the G4X now open and initial shipments expected in June 2025 [3] Group 2: Multiomic Performance and 3D Reconstruction - Singular Genomics showcased the G4X platform's robust integrated multiomic performance, demonstrating high sensitivity, specificity, and reproducibility in various cancer panels [5] - Advanced 3D multi-omic reconstruction was presented, utilizing data from 10 serial renal cell carcinoma FFPE sections, encompassing over 6.2 million cells and 438 million transcripts from a single flow cell [6] - The G4X system's ability to measure transcripts, proteins, and fH&E within the same sample enhances reproducibility and facilitates advanced spatial analyses [7] Group 3: Direct Sequencing and Data Availability - Singular advanced its Direct-Seq technology, enabling accurate sequencing of T- and B-cell receptors in tissue samples [8] - Researchers can access raw and demo datasets from Singular's multi-tissue performance studies to validate the platform's capabilities [9] Group 4: Company Overview - Singular Genomics is focused on developing next-generation sequencing and multiomics technologies, with the G4X™ Spatial Sequencer leveraging proprietary sequencing technology for in situ readouts [10]